Abstract
Primary Epstein-Barr virus (EBV) infection in childhood is typically asymptomatic,
but infection later in life results in a mononucleosis with the illness severity
ranging from asymptomatic to requiring hospitalisation. The illness is generally
short-lived (four to six weeks following onset of symptoms), but persistent
disabling symptoms (lasting up to 6 months or longer) are well described in
around ten percent of individuals. The aim of this work was to characterise
immunological and virological parameters in the peripheral blood, which correlate
with persistence of symptoms following EBV-induced mononucleosis. Subjects
were recruited prospectively following confirmed primary EBV infection, to allow
blood samples and clinical data to be collected at multiple timepoints (baseline, 2
weeks, 4 weeks, 3 months and at least 12 months later). Subjects with 6 months
or more of disabling symptoms were defined as cases with control subjects
being those whose illness resolved within 6 weeks of enrolment. Cases were
compared with control subjects in terms of: cellular EBV viral load in the
peripheral blood by PCR; development of antibodies against EBV VCA (IgG and
IgM) and EBNA-1 (IgG) by ELISA; proportions of peripheral blood leucocyte
subsets and their activation status by flow cytometry; the magnitude, kinetics of
development, and breadth of the CD8+ cytotoxic cell response by interferon-γ Elispot; cytokine levels in serum, and production by peripheral blood
mononuclear cells ex vivo; and gene expression patterns in peripheral blood
mononuclear cells by microarray. With the exception of gene expression, none of
these parameters correlated with early resolution of symptoms or predicted
clinical outcome following primary EBV infection. Antibody patterns suggest a
tendency to Th2 type immune response may be associated with persistent
illness. Preliminary analysis of the gene expression studies indicates that there
are many genes involved in this complex disease requiring further investigation.
Persistent illness following EBV infection is not associated with uncontrolled viral
replication, or chronic immune activation due to an aberrant primary immune
response.